Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
1 recherche sur le mot-clé 'European'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents / Samuele CORTESE in Journal of Child Psychology and Psychiatry, 54-3 (March 2013)
[article]
Titre : Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents Type de document : Texte imprimé et/ou numérique Auteurs : Samuele CORTESE, Auteur ; Martin HOLTMANN, Auteur ; Tobias BANASCHEWSKI, Auteur ; Jan K. BUITELAAR, Auteur ; David R. COGHILL, Auteur ; Marina DANCKAERTS, Auteur ; Ralf W. DITTMANN, Auteur ; John GRAHAM, Auteur ; Eric TAYLOR, Auteur ; Joseph A. SERGEANT, Auteur ; Adhd Guidelines Group ON BEHALF OF THE EUROPEAN, Auteur Article en page(s) : p.227-246 Mots-clés : ADHD medication adverse events management recommendations European Index. décimale : PER Périodiques Résumé : Background: Medication is an important element of therapeutic strategies for ADHD. While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs. The aim of this review is to provide evidence- and expert-based guidance concerning the management of (AEs) with medications for ADHD. Methods: For ease of use by practitioners and clinicians, the article is organized in a simple question and answer format regarding the prevalence and management of the most common AEs. Answers were based on empirical evidence from studies (preferably meta-analyses or systematic reviews) retrieved in PubMed, Ovid, EMBASE and Web of Knowledge through 30 June 2012. When no empirical evidence was available, expert consensus of the members of the European ADHD Guidelines Group is provided. The evidence-level of the management recommendations was based on the SIGN grading system. Results: The review covers monitoring and management strategies of loss of appetite and growth delay, cardiovascular risks, sleep disturbance, tics, substance misuse/abuse, seizures, suicidal thoughts/behaviours and psychotic symptoms. Conclusion: Most AEs during treatment with drugs for ADHD are manageable and most of the times it is not necessary to stop medication, so that patients with ADHD may continue to benefit from the effectiveness of pharmacological treatment. En ligne : http://dx.doi.org/10.1111/jcpp.12036 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=191
in Journal of Child Psychology and Psychiatry > 54-3 (March 2013) . - p.227-246[article] Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents [Texte imprimé et/ou numérique] / Samuele CORTESE, Auteur ; Martin HOLTMANN, Auteur ; Tobias BANASCHEWSKI, Auteur ; Jan K. BUITELAAR, Auteur ; David R. COGHILL, Auteur ; Marina DANCKAERTS, Auteur ; Ralf W. DITTMANN, Auteur ; John GRAHAM, Auteur ; Eric TAYLOR, Auteur ; Joseph A. SERGEANT, Auteur ; Adhd Guidelines Group ON BEHALF OF THE EUROPEAN, Auteur . - p.227-246.
in Journal of Child Psychology and Psychiatry > 54-3 (March 2013) . - p.227-246
Mots-clés : ADHD medication adverse events management recommendations European Index. décimale : PER Périodiques Résumé : Background: Medication is an important element of therapeutic strategies for ADHD. While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs. The aim of this review is to provide evidence- and expert-based guidance concerning the management of (AEs) with medications for ADHD. Methods: For ease of use by practitioners and clinicians, the article is organized in a simple question and answer format regarding the prevalence and management of the most common AEs. Answers were based on empirical evidence from studies (preferably meta-analyses or systematic reviews) retrieved in PubMed, Ovid, EMBASE and Web of Knowledge through 30 June 2012. When no empirical evidence was available, expert consensus of the members of the European ADHD Guidelines Group is provided. The evidence-level of the management recommendations was based on the SIGN grading system. Results: The review covers monitoring and management strategies of loss of appetite and growth delay, cardiovascular risks, sleep disturbance, tics, substance misuse/abuse, seizures, suicidal thoughts/behaviours and psychotic symptoms. Conclusion: Most AEs during treatment with drugs for ADHD are manageable and most of the times it is not necessary to stop medication, so that patients with ADHD may continue to benefit from the effectiveness of pharmacological treatment. En ligne : http://dx.doi.org/10.1111/jcpp.12036 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=191